Manuel Litchman

Manuel Litchman, M.D., is the President and Chief Executive Officer of Mustang Bio, a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and rare diseases. He has held this position since April 2017 and is also a member of the company's Board of Directors.

Professional Background

• Previous Roles: Before joining Mustang Bio, Dr. Litchman served as the President and CEO of Arvinas, LLC, where he led efforts to advance protein-degradation therapeutics. His career also includes over 18 years at Novartis Pharmaceuticals Corporation, where he held various leadership positions related to oncology, including Senior Vice President and Executive Global Program Head for CTL019, a pioneering CAR T-cell therapy collaboration with the University of Pennsylvania.123

• Education: Dr. Litchman earned his M.D. from Yale University School of Medicine and his B.A. from Princeton University.12

Contributions to Mustang Bio

Under his leadership, Mustang Bio has focused on developing advanced therapies, particularly in the field of gene and cell therapy. His extensive experience in oncology and drug development has been instrumental in guiding the company's strategic direction and fostering collaborations with major pharmaceutical partners.12

Dr. Litchman's career reflects a strong commitment to advancing medical science, particularly in oncology, making him a significant figure in the biopharmaceutical industry.